Oncology Central

FDA approves first-in-class treatment for rare adrenal tumors

The US FDA has approved Adzera® (iobenguane I 131) for intravenous use for the treatment of patients age 12 or older with rare tumors of the adrenal gland, pheochromocytoma and paraganglioma. This is the first approved drug to treat tumors of this kind that are unresectable, have spread beyond the primary location and require systemic anticancer therapy.
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.